pairingsPairing
Amivantamab + lazertinib (first-line EGFR NSCLC)
Blocking EGFR from inside (a pill) and outside (an antibody that also blocks MET) beat osimertinib and added more than a year of survival.
MARIPOSA: PFS 23.7 vs 16.6 months (HR 0.70); OS HR 0.75, median >12 months longer (2025). Cost is more toxicity (rash, paronychia, VTE, infusion reactions) and IV visits; subcutaneous amivantamab (2025) eases the latter.
Rationale
Lazertinib blocks intracellular EGFR signalling while amivantamab blocks EGFR and MET extracellularly and recruits immune effectors, pre-empting the MET-amplification and C797S escape routes.
Evidence
Phase 3 with OS benefit.